Small Cell Carcinoma — Clinical Trials

MONDO:000040273 active·32 recruitingLast updated: Mar 20, 2026, 6:19 PM

Trial Landscape

Small Cell Carcinoma has an active clinical trial landscape, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment26

Procedure21

Biological Therapy11

Medical Device3

18 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 1

Phase 2

Phase 3

8 trials are observational or have no phase designation.

Sponsor Types

Academic/Other26NIH10Industry6Collaborative Network1

Top Sponsors

A2 Biotherapeutics Inc.

AstraZeneca

Black Diamond Therapeutics, Inc.

Invitae Corporation

Massive Bio, Inc.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Trial Locations

United States37 trials

China5 trials

Canada4 trials

Puerto Rico3 trials

Italy2 trials

Guam2 trials

Chile2 trials

Japan2 trials

South Korea2 trials

Brazil1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

184 Trials

Phase 3Recruiting

NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jun 2020Est. completion: Jan 2027Updated: Mar 2026

Phase 3Recruiting

NCT04155034

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Sponsor:SWOG Cancer Research Network

United StatesStarted: May 2020Est. completion: Nov 2029Updated: May 2025

Phase 2Recruiting

NCT05198830

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2022Est. completion: Jun 2027Updated: Mar 2026

Phase 2Recruiting

NCT03866382

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2019Est. completion: Feb 2027Updated: Mar 2026

Phase 2Recruiting

NCT06161532

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Aug 2024Est. completion: Nov 2028Updated: Mar 2026

Phase 2Recruiting

NCT06660407

Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer

Sponsor:Mayo Clinic

United StatesStarted: Nov 2024Est. completion: Jan 2027Updated: Mar 2026

Phase 2Recruiting

NCT05672108

Phase II Trial of Lung Chemoemobolization

Sponsor:City of Hope Medical Center

United StatesStarted: May 2023Est. completion: Oct 2027Updated: Mar 2026

Phase 2Recruiting

NCT05969860

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Sponsor:Mayo Clinic

United StatesStarted: Aug 2023Est. completion: Jan 2027Updated: Feb 2026

Phase 2Recruiting

NCT07423585

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

Sponsor:Asrar Alahmadi

United StatesStarted: Apr 2026Est. completion: Dec 2027Updated: Feb 2026

Phase 2Recruiting

NCT06518057

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

Sponsor:University of Washington

United StatesStarted: Mar 2025Est. completion: Dec 2027Updated: Dec 2025

Phase 3Active, Not Recruiting

NCT03811002

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2019Est. completion: Feb 2029Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT04428905

Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer

Sponsor:City of Hope Medical Center

United StatesStarted: Jul 2020Est. completion: Mar 2027Updated: Feb 2026

Phase 3Active, Not Recruiting

NCT03793179

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Apr 2019Est. completion: Sep 2027Updated: Nov 2025

Phase 2Active, Not Recruiting

NCT04334941

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2020Est. completion: Jan 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT02642042

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2016Est. completion: Mar 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT03778229

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Sponsor:AstraZeneca

United StatesStarted: Jan 2019Est. completion: Dec 2026Updated: Feb 2026

Phase 2Active, Not Recruiting

NCT02721732

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Aug 2016Est. completion: Dec 2028Updated: Jan 2026

Phase 2Active, Not Recruiting

NCT05340309

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Sponsor:University of Southern California

United StatesStarted: Dec 2022Est. completion: Dec 2027Updated: Jan 2026

Phase 2Active, Not Recruiting

NCT03333616

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Sponsor:Dana-Farber Cancer Institute

United StatesStarted: Dec 2017Est. completion: Dec 2026Updated: Jan 2026

Phase 2Active, Not Recruiting

NCT04010357

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Sponsor:Case Comprehensive Cancer Center

United StatesStarted: Jan 2020Est. completion: Dec 2025Updated: Dec 2025

Stay informed about clinical trials for Small Cell Carcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 20, 2026 at 6:19 PM

Small Cell Carcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Top Sponsors

Trial Locations

184 Trials

Open Trials41

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer

Phase II Trial of Lung Chemoemobolization

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

Active Trials32

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Other111